Professor Anne Kiltie

Professor Anne Kiltie
Professor Anne Kiltie
Professor Anne Kiltie

MA DM DSc MRCP(UK) FRCR

Friends of ANCHOR Clinical Chair in Oncology

About

Biography

I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.

I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.

My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.

 

Qualifications

  • DSc Medical Sciences 
    2016 - University of Oxford 
  • DM Medical Sciences 
    1999 - University of Oxford 
  • BM BCh Medicine 
    1988 - University of Oxford 
  • BA Medical Sciences 
    1985 - University of Cambridge 
  • MRCP(UK) General Medicine 
    1992 - Royal College of Physicians of England 
  • FRCR Clinical Oncology 
    1995 - Royal College of Radiologists 
  • MA Medicine 
    1989 - University of Cambridge 
  • MA Medicine 
    1999 - University of Oxford 

Memberships and Affiliations

Internal Memberships

Jul 2021 - present      Member of the Rowett Institute Ethics Panel

Oct 2021 - present     Member of Friends of ANCHOR Research Advisory Group

Oct 2024 - present     Elected member Senatus Academicus

Oct 2024 - present     Member of Honorary Degrees Committee

External Memberships

Apr 2024 - present    Chair, Scottish Radiation Research Forum (ScoRRF)

Jun 2023 - present    Member of RAIDER TrialTranslational Working Group 

Jan 2022 - present    Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022

Jan 2022 - present    Member of Scottish Radiotherapy Research Forum Committee

Oct 2018 - present     Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Network Management Committee

Dec 2017 - present    Member of Editorial Board of European Urology Oncology

Oct 2016 - present     Associate Editor of Bladder Cancer

2014 - present            Grant reviewer for Italian Association for Cancer Research (AIRC)

Sept 2012 - present   British Uro-oncology Group Executive Committee Trustee

Jan 2012 - present     Royal College of Radiologists representative on Advisory Appointments Committees

Latest Publications

  • Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity

    Then, C. K., Paillas, S., Moomin, A., Misheva, M. D., Moir, R. A., Hay, S. M., Bremner, D., Roberts (nee Nellany), K. S., Smith, E. E., Heidari, Z., Sescu, D., Wang, X., Suárez-Bonnet, A., Hay, N., Murdoch, S. L., Saito, R., Collie-Duguid, E. S. R., Richardson, S., Priestnall, S. L., Wilson, J. M., Gurumurthy, M., Royle, J. S., Samuel, L. M., Ramsay, G., Vallis, K. A., Foster, K. R., McCullagh, J. S. O., Kiltie, A. E.
    Microbiome, vol. 12, no. 1, 89
    Contributions to Journals: Articles
  • How do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?

    Asim, F., Clarke, L., Donnelly, E., Jamal, F., Piccicacchi, L., Qadir, M., Raja, N., Samadi, C., Then, C. K., Kiltie, A.
    BMJ Oncology, vol. 2, no. 1, e000107
    Contributions to Journals: Review articles
  • Field-cycling imaging in ovarian cancer: a novel technology

    Bhagat, N., Broche, L., Shylasree, T. S., Kiltie, A. E., Bhattacharya, S., Gurumurthy, M.
    International Journal of Gynecological Cancer, vol. 33, no. 8, pp. 1329-1330
    Contributions to Journals: Comments and Debates
  • Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights

    Koutros, S., Kiemeney, L. A., Pal Choudhury, P., Milne, R. L., Lopez de Maturana, E., Ye, Y., Joseph, V., Florez-Vargas, O., Dyrskjøt, L., Figueroa, J., Dutta, D., Giles, G. G., Hildebrandt, M. A., Offit, K., Kogevinas, M., Weiderpass, E., McCullough, M. L., Freedman, N. D., Albanes, D., Kooperberg, C., Cortessis, V. K., Karagas, M. R., Johnson, A., Schwenn, M. R., Baris, D., Furberg, H., Bajorin, D. F., Cussenot, O., Cancel-Tassin, G., Benhamou, S., Kraft, P., Porru, S., Carta, A., Bishop, T., Southey, M. C., Matullo, G., Fletcher, T., Kumar, R., Taylor, J. A., Lamy, P., Prip, F., Kalisz, M., Weinstein, S. J., Hengstler, J. G., Selinski, S., Harland, M., Teo, M., Kiltie, A. E., Tardón, A., Serra, C., UROMOL Consortium
    European Urology, vol. 84, no. 1, pp. 127-137
    Contributions to Journals: Articles
  • Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients

    Eaton, S. E., Kaczmarek, J., Mahmood, D., McDiarmid, A. M., Norarfan, A. N., Scott, E. G., Then, C. K., Tsui, H. Y., Kiltie, A. E.
    British Journal of Cancer, vol. 127, pp. 2087–2098
    Contributions to Journals: Review articles

View My Publications

Prizes and Awards

Development Trust Award for Philanthropy and Alumni Engagement, The Principal’s Prizes for Research and Engagement, University of Aberdeen Excellence Awards, Apr 2024

Research

Research Overview

Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.

Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiota as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.

Research Areas

Applied Health Sciences

Biomedical Sciences

Nutrition and Health

Research Specialisms

  • Medicine
  • Food Science
  • Bacteriology
  • Oncology

Our research specialisms are based on the Higher Education Classification of Subjects (HECoS) which is HESA open data, published under the Creative Commons Attribution 4.0 International licence.

Supervision

Supervisees

  • MS POLLY NOCK
  • MISS ANAM WAJID
  • DR NANAK BHAGAT
  • MS MEREL VAN DEN HAAK
  • MR ADAM POTTER

Funding and Grants

  1. Exploiting human microbiota-associated in vivo models for mechanistic studies to understand the benefits of dietary fibre supplementation in patients with prostate cancer. NHS Grampian Charity (£92,422.14) Kiltie AE, 15 Nov 2024 – 31 Oct 2025.
  2. The role of intestinal dendritic cells in mediating tumour and normal tissue responses to dietary fibre manipulation. Friends of ANCHOR Pilot Research Funding (£14,345) AE Kiltie, co-applicants: A Moomin, H Wilson, J Coombes, 1 Aug 2024-31 Jul 2025. RG17583.
  3. Role of intestinal macrophages in the protective effects of dietary fibre supplementation during radiotherapy. Medical Research Scotland PhD Studentship (£126,565.82) AE Kiltie, co-applicants: H Wilson, J Coombes, 1 Oct 2024 – 30 Sept 2028. RG17405.
  4. In gut health not all dietary fibres are equal: diet meets artificial intelligence. RESAS PhD studentship (Anam Wajid; £133,446), J Kyle, AE Kiltie (joint lead supervisors), K Scott, A Ayesh, 1 Jan 2024 to 31 Mar 2027.
  5. Dietary fibre supplementation to delay disease progression in early prostate cancer: preparatory work to develop a feasibility study (DEFINITE study) Friends of ANCHOR (£22,000) AE Kiltie, co-applicants: J Royle, J Kyle, S MacLennan, 1 Oct 2023 – 31 Dec 2024. RG17168.
  6. Feasibility of using National Bowel Screening Programme surplus qFIT samples to investigate the gut microbiota FUTURISTIC study). NHS Grampian Charity (£11,269.44), AE Kiltie, co-applicants: F Din, S McSorley, 1 Oct 2023 – 31 Mar 2025. GCA23249.
  7. Exploiting the gut microbiota and its metabolites in pelvic cancer to improve patient outcomes (PELICAN-23). NHS Grampian Endowment Fund (£130,505.37 plus £30,897.41 = £161,402.78) AE Kiltie, G Ramsay (Co-PI), co-applicants: J Royle, K Dimitropoulos, J Grant, G Horgan, G MacDonald, R McMenimen, M Gurumurthy, L Samuel, 1 Sept 2022 – 30 Sept 2025. ES900/EA4021.
  8. A human volunteer study of the effects of psyllium and inulin on the gut microbiome and metabolites: can we identify responders and non-responders to optimise outcomes for pelvic radiotherapy patients (PIGMent study)? Friends of ANCHOR /University of Aberdeen Development Trust PhD studentship (£168,500) AE Kiltie, co-applicants: A Johnstone, K Scott, A Walker, G Horgan, 1 Oct 2022 – 30 Sept 2026.

Datasets

  • Data from: Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity

    Abstract Background Non-toxic approaches to enhance radiotherapy outcomes are beneficial, particularly in ageing populations. Based on preclinical findings showing that high-fibre diets sensitised bladder tumours to irradiation by modifying the gut m...
Teaching

Teaching Responsibilities

ME3013 MBChB SSC2: supervisor

BM4501 BSc Honours project: supervisor

RN5504 Nutrition and Health through the Life Stages: lecture

RN5505 Clinical Nutrition: lecture and seminar

RN5503 Clinical Nutrition for Disease Prevention: lecture

Non-course Teaching Responsibilities

I am a Regent for the MB ChB Regent Scheme.

Publications

Page 5 of 10 Results 41 to 50 of 96

  • Three-dimensional scaffolds: An in vitro strategy for the biomimetic modelling of in vivo tumour biology

    Sharma, A., Sharma, N. L., Lavy, C. B., Kiltie, A. E., Hamdy, F. C., Czernuszka, J.
    Journal of Materials Science, vol. 49, no. 17, pp. 5809-5820
    Contributions to Journals: Review articles
  • Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden

    Cazier, J. B., Rao, S. R., McLean, C. M., Walker, A. L., Wright, B. J., Jaeger, E. E., Kartsonaki, C., Marsden, L., Yau, C., Camps, C., Kaisaki, P., Taylor, J., Catto, J. W., Tomlinson, I. P., Kiltie, A. E., Hamdy, F. C., Allan, C., Attar, M., Bell, J., Bentley, D., Broxholme, J., Buck, D., Copley, R., Cornall, R., Donnelly, P., Fiddy, S., Green, A., Gregory, L., Grocock, R., Hatton, E., Holmes, C., Hughes, L., Humburg, P., Humphray, S., Kanapin, A., Kingsbury, Z., Knight, J., Lamble, S., Lise, S., Lonie, L., Lunter, G., Martin, H., Murray, L., McCarthy, D., McVean, G., Pagnamenta, A., Piazza, P., Polanco, G., Ratcliffe, P., Rimmer, A.
    Nature Communications, vol. 5, 3756
    Contributions to Journals: Articles
  • Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer

    Teo, M. T., Dyrskjøt, L., Nsengimana, J., Buchwald, C., Snowden, H., Morgan, J., Jensen, J. B., Knowles, M. A., Taylor, G., Barrett, J. H., Borre, M., ørntoft, T. F., Bishop, D. T., Kiltie, A. E.
    Annals of Oncology, vol. 25, no. 4, pp. 877-883
    Contributions to Journals: Articles
  • Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours

    Martin, R. M., Kerr, M., Teo, M. T., Jevons, S. J., Koritzinsky, M., Wouters, B. G., Bhattarai, S., Kiltie, A. E.
    Oncotarget, vol. 5, no. 4, pp. 993-1003
    Contributions to Journals: Articles
  • Can γH2AX be used to personalise cancer treatment?

    Shah, K., Cornelissen, B., Kiltie, A. E., Vallis, K. A.
    Current molecular medicine, vol. 13, no. 10, pp. 1591-1602
    Contributions to Journals: Review articles
  • Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression

    Groselj, B., Kerr, M., Kiltie, A. E.
    Radiotherapy and Oncology, vol. 108, no. 3, pp. 429-433
    Contributions to Journals: Articles
  • The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers

    Sharma, N. L., Groselj, B., Hamdy, F. C., Kiltie, A. E.
    BJU International, vol. 111, no. 4, pp. 537-542
    Contributions to Journals: Review articles
  • Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair

    Groselj, B., Sharma, N. L., Hamdy, F. C., Kerr, M., Kiltie, A. E.
    British Journal of Cancer, vol. 108, no. 4, pp. 748-754
    Contributions to Journals: Articles
  • Imatinib radiosensitizes bladder cancer by targeting homologous recombination

    Qiao, B., Kerr, M., Groselj, B., Teo, M. T., Knowles, M. A., Bristow, R. G., Phillips, R. M., Kiltie, A. E.
    Cancer Research, vol. 73, no. 5, pp. 1611-1620
    Contributions to Journals: Articles
  • The role of microrna-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes

    Teo, M. T., Landi, D., Taylor, C. F., Elliott, F., Vaslin, L., Cox, D. G., Hall, J., Landi, S., Bishop, D. T., Kiltie, A. E.
    Carcinogenesis, vol. 33, no. 3, pp. 581-586
    Contributions to Journals: Articles
Show 10 | 25 | 50 | 100 results per page

Refine

Chapters in Books, Reports and Conference Proceedings

Contributions to Journals